Insider Transactions in Q1 2024 at Edgewise Therapeutics, Inc. (EWTX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,800
-40.61%
|
$96,000
$20.04 P/Share
|
|
Feb 09
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,800
+28.88%
|
$4,800
$1.93 P/Share
|
|
Feb 09
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
8,029
-100.0%
|
$160,580
$20.01 P/Share
|
|
Feb 09
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,029
+50.0%
|
$8,029
$1.93 P/Share
|
|
Feb 08
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,600
-39.59%
|
$92,000
$20.01 P/Share
|
|
Feb 08
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+28.36%
|
$4,600
$1.93 P/Share
|
|
Feb 08
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
3,813
-100.0%
|
$76,260
$20.01 P/Share
|
|
Feb 08
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,813
+50.0%
|
$3,813
$1.93 P/Share
|
|
Feb 07
2024
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
600
-7.87%
|
$12,000
$20.0 P/Share
|
|
Feb 07
2024
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+7.3%
|
$600
$1.93 P/Share
|
|
Feb 07
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
17,993
-100.0%
|
$359,860
$20.0 P/Share
|
|
Feb 07
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
17,993
+50.0%
|
$17,993
$1.93 P/Share
|
|
Jan 23
2024
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
90,000
-75.62%
|
$1,350,000
$15.78 P/Share
|
|
Jan 23
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+43.06%
|
$90,000
$1.93 P/Share
|
|
Jan 23
2024
|
Peter A. Thompson |
BUY
Open market or private purchase
|
Indirect |
454,545
+3.05%
|
$4,999,995
$11.0 P/Share
|
|
Jan 23
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
454,545
+3.05%
|
$4,999,995
$11.0 P/Share
|